Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib – Case report

Central nervous system (CNS) involvement by mantle cell lymphoma (MCL) is rare and portends a poor prognosis. We describe the first patient to have a complete response with front‐line treatment with single‐agent acalabrutinib for MCL CNS.

Saved in:
Bibliographic Details
Published inEJHaem Vol. 5; no. 1; pp. 238 - 241
Main Authors Barrett, Aisling, Eyre, Toby A., Bhuva, Shaheel, Aljurf, Mahmoud, Fakih, Riad El, Ashshi, Mohammad A., Alshaibani, Alfadel
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.02.2024
Wiley
Subjects
acalabrutinib
Brain research
case report
Case reports
Central nervous system
central nervous system lymphoma
Chemotherapy
Clinical trials
Conflicts of interest
Consent
Lymphoma
Magnetic resonance imaging
Mantle cell lymphoma
Nervous system
Oncology
Patients
PET in lymphoma
Tomography
case report
mantle cell lymphoma
PET in lymphoma
central nervous system lymphoma
acalabrutinib
Online AccessGet full text

Cover

More Information
Summary:Central nervous system (CNS) involvement by mantle cell lymphoma (MCL) is rare and portends a poor prognosis. We describe the first patient to have a complete response with front‐line treatment with single‐agent acalabrutinib for MCL CNS.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Report-1
ISSN:2688-6146
2688-6146
DOI:10.1002/jha2.830